Lipid inCode® (developed by GEN inCode) - The Genetic Test used by the Lipigen network

The Genetic Diagnosis of Familial Hypercholesterolemia (FH) is the tool bringing definite diagnostic of the disease as well as giving valuable information by distinguishing between its different etiologies, allowing genetic counselling, and identifying other family members affected by the pathology. It can also help in the patient's adherence to treatment and lifestyle recommendations. Furthermore, it can enable the identification of persons with a very high risk of early coronary disease or sub-clinic atherosclerosis.

In some countries such as Italy and Spain, the clinic and/or genetic diagnostic of FH brings access to chronic lipid-lowering therapy reimbursement.

Lipid inCode® (developed by GEN inCode) is the Genetic Test used by the Lipigen network in order to better understand the risk heterogeneity of patients with Hypercholesterolemia.

It provides risk stratification for deeper analysis of each patient's risk profile, where several aspects can contribute to increase their coronary risk.

It includes:

- The NGS analysis of 7 genes related to FH and similar phenotypes (*LDLR, APOB, APOE, PCSK9, LDLRAP1, STAP1, LIPA*)
- The evaluation of Polygenic Hypercholesterolemia with the LDL-c Score By Talmud et al.
- The assessment of independent and additional Coronary Genetic risk, thanks to Cardio inCode® Score, developed by GEN inCode and Clinically validated in more than 80.000 patients.
- It also brings information regarding resistance to statins (Simvastatin) and predisposition to high Lp(a) levels.

By providing a more complete risk assessment, Lipid inCode® helps the clinician in defining the more adapted treatment pathway for their patients with Hypercholesterolemia, bringing better control and prevention towards coronary disease.